The Novel Dual GIP and GLP‐1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism

The Novel Dual GIP and GLP‐1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism

Abstract Colorectal cancer (CRC) is a leading cause of cancer mortality while diabetes is a recognized risk factor for CRC. Here we report that tirzepatide (TZP), a novel polypeptide/glucagon‐like peptide 1 receptor (GIPR/GLP‐1R) agonist for the treatment of diabetes, has a role in attenuating CRC g...

Full description

Saved in:
Bibliographic Details
Main Authors: Yikai Zhang, Yi Xie, Shenglong Xia, Xinnuo Ge, Jiaying Li, Fang Liu, Fan Jia, Shengyao Wang, Qiao Zhou, Menghan Gao, Weihuan Fang, Chao Zheng
Format: Article
Language:English
Published: Wiley 2025-05-01
Series:Advanced Science
Subjects:
anti‐colorectal cancer effect
glucose metabolism
tirzepatide
Online Access:https://doi.org/10.1002/advs.202411980
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/advs.202411980

Similar Items